Ivermectin

There is an active and bitter debate going on right now as to whether the drug Ivermectin is a successful treatment for Covid-19. Some doctors are seemingly throwing caution to the wind and writing prescriptions for Ivermectin as a treatment protocol for their patients infected with the novel Covid-19 virus. Many report remarkable success stories. So what's the debate about?

The counter-argument is generally that Ivermectin is strictly for the treatment of parasites in animals... but there are literally dozens of off-label uses with peer-reviewed studies than demonstrate the broad efficacy of this drug for humans. It is already known to kill 22 different viruses. This was testified to in front of Congress in December of 2020 by qualified and competent medical authorities. It cures the flu. Some report the quick turn-around of Covid symptoms with its use. It probably cures smallpox and polio too; probably even Ebola and malaria. The people who created it were awarded a Nobel Prize. Over 4 billion doses of it have already been given to humans for various treatments with remarkable success... and it has the lowest death rate per dose of any drug that you can suggest over the last century. Furthermore, it is virtually impossible to overdose on it, so that when all things are considered it may be one of the safest things you can take for any viral infection.

Those receiving Ivermectin who have been infected with the virus or treated with one of the vaccines with spiked proteins and graphene oxide are finding that the drug is binding itself to these two foreign agents and flushing them out of the body through the gut, no matter what tissues throughout the body they have become embedded in.

Ivermectin is an interesting substance, derived from a source never before tapped as an aid to humans. Its creators looked at the enzymatic products of nematodes in the soil; they studied what these enzymes were doing to the surrounding area of the soil and came up with powerful medicine for humans. Perhaps its greatest potential benefit may be its use as a cure for cancer.

Scientists have been taking cancer patients, treating them with Ivermectin, and discovering the quick and total eradication of nascent cancer cells throughout the body. Initial findings are that it erodes tumors in a safe way. The highlights of a report in ScienceDirect.com are as follows:

• Ivermectin effectively suppresses the proliferation and metastasis of cancer cells and promotes cancer cell death at doses that are nontoxic to normal cells.

• Ivermectin shows excellent efficacy against conventional chemotherapy drug-resistant cancer cells and reverses multidrug resistance.

• Ivermectin combined with other chemotherapy drugs or targeted drugs has powerful effects on cancer.

• The structure of cross-talk centered on PAK1 kinase reveals the mechanism by which ivermectin regulates multiple signaling pathways.

• Ivermectin has been used to treat parasitic diseases in humans for many years and can quickly enter clinical trials for the treatment of tumors.

Their supporting Abstract reads as follows:

Ivermectin is a macrolide anti-parasitic drug with a 16-membered ring that is widely used for the treatment of many parasitic diseases such as river blindness, elephantiasis and scabies. Satoshi Omura and William C. Campbell won the 2015 Nobel Prize in Physiology or Medicine for the discovery of the excellent efficacy of ivermectin against parasitic diseases. Recently, ivermectin has been reported to inhibit the proliferation of several tumor cells by regulating multiple signaling pathways. This suggests that ivermectin may be an anticancer drug with great potential.

Ivermectin has powerful anti-tumor effects, including the inhibition of proliferation, metastasis, and angiogenic activity, in a variety of cancer cells. This may be related to the regulation of multiple signaling pathways by ivermectin through PAK1 kinase. On the other hand, ivermectin promotes programmed cancer cell death, including apoptosis, autophagy and pyroptosis. Ivermectin induces apoptosis and autophagy is mutually regulated. Interestingly, ivermectin can also inhibit tumor stem cells and reverse multi-drug resistance and exerts the optimal effect when used in combination with other chemotherapy drugs.

Dr. William Makis, one of the most well-known critics of the failed response to the COVID-19 pandemic, has been an enthusiastic advocate for the use of Ivermectin and mebendazole in treating a wide array of cancers. Dr. Makis listed 20 studies that show the potential for Ivermectin in fighting cancer:

Here are recent studies on IVERMECTIN use in certain types of cancer:

• BLADDER CANCER– (2024 Fan et al) – Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage

• LUNG CANCER– (2024 Man-Yuan Li et al) – Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells

• GLIOMA– (2024 Xing Hu et al) – Ivermectin as a potential therapeutic strategy for glioma

• MULTIPLE MYELOMA– (2024 Yang Song et al) – Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma

• OVARIAN CANCER– (2023 Jawad et al) – Ivermectin augments the anti-cancer activity of pitavastatin in ovarian cancer cells

• PROSTATE CANCER –(2022 Lu et al) – Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer

• COLON CANCER– (2022, Alghamdi et al) – Efficacy of ivermectin against colon cancer induced by dimethylhydrazine in male wistar rats

• PANCREATIC CANCER– (2022 Lee et al) – Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via-mitochondrial dysfunction

• MELANOMA– (2022 Zhang et al) – Drug repurposing of ivermectin abrogates neutrophil extracellular traps and prevents melanoma metastasis

• CERVICAL CANCER– (2022, Qabbus et al) – Ivermectin-induced cell death of cervical cancer cells in vitro a consequence of precipitate formation in culture media

• HEPATOCELLULAR CARCINOMA– (2022 Lu et al) – Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways

• OSTEOSARCOMA– (2022 Hu et al) – Repurposing Ivermectin to augment chemotherapy’s efficacy in osteosarcoma

• GASTRIC CANCER– (2021 Rabben et al) – Computational drug repositioning and experimental validation of ivermectin in treatment of gastric cancer

• LEUKEMIA– (2020, de Castro et al) – Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection

• ESOPHAGEAL SCC– (2020, Chen et al) – Ivermectin suppresses tumor growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma

• CHOLANGIOCARCINOMA– (2019 Intyuod et al) – Anti-parasitic drug ivermectin exhibits potent anticancer activity against gemcitabine-resistant cholangiocarcinoma in vitro

• BREAST CANCER STEM CELLS –(2018 Dominguez-Gomez et al) – Ivermectin as an inhibitor of cancer stem-like cells

• CML (CHRONIC MYELOID LEUKEMIA)– (2018 Wang et al) – Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress

• RENAL CELL CARCINOMA– (2017 Zhu et al) – Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage

• GLIOBLASTOMA– (2016 Liu et al) – Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress

Dr. Makis makes it clear that he believes Ivermectin could be a valuable tool in the battle against cancer and explains why the medical establishment is in no hurry to explore Ivermectin’s potential:

IVERMECTIN has proven anti-cancer activity against some 20 cancer types, although these are pre-clinical studies. We will never see clinical studies because Ivermectin is off patent and cheap. Merck, which used to have a patent on Ivermectin, has partnered with Moderna on mRNA Cancer Vaccines, estimated to cost 400,000 GBP per treatment. Ivermectin studies on mice include: Breast cancer, Colon cancer, glioblastoma, glioma and leukemia. I have not seen IVERMECTIN studies on Lymphoma, Testicular Cancer, Sarcomas. IVERMECTIN acts on Cancer mainly by inhibiting signaling pathways involved in cancer proliferation (Akt, Wnt, mTOR) and by inhibiting CANCER STEM CELLS.

Dr. Makis is one of the trusted medical professionals talking about the potential of Ivermectin. According to the McCullough Foundation a new study confirms the early returns on Ivermectin are positive:

The study titled “A Review of Ivermectin Use in Cancer Patients: Is it Time to Repurpose the Ivermectin in Cancer Treatment?” was just published in the journal Acta Poloniae Pharmaceutica – Drug Research…Based on the most comprehensive systematic review of ivermectin use in cancer patients to date, ivermectin appears to be safe—even in individuals undergoing active chemotherapy. Its broad range of anticancer mechanisms demonstrated in preclinical models, combined with anecdotal reports of cancer-related improvements, support its candidacy for repurposing as an oncologic therapy. Well-designed, large-scale clinical trials should be launched as soon as possible to properly assess ivermectin’s potential against cancer.

Indeed, ivermectin in concert with mebendazole has shown even more promise in treating a wide variety of cancers.

We all need to question, question, question further whenever either the authorities or the media object to or attempt to regulate against the use of this drug without a reasonable, scientific-based explanation, and demand support of their argument.